Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tengion
The NUC under investigation is a regenerative medicine product comprised of the patient's own smooth muscle cells, procured from a fat biopsy. Tengion has developed appropriate culture conditions to reproducibly generate the necessary quantities of SMC in vitro from autologous adipose tissue biopsies. The NUC is produced at Tengion's Good Manufacturing Practices (GMP) qualified clinical production facility. In this process, smooth muscle cells (SMC) obtained from an adipose tissue biopsy are propagated ex-vivo for approximately 3 - 4 weeks. At the end of this process, the SMCs are seeded onto the surface of a biodegradable PGA/PLGA mesh scaffold to form the NUC. The NUC is shipped to the investigative site for surgical implantation. Over time, the NUC should facilitate the regeneration of urinary tract tissue.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female subjects 18 - 80 years of age
Patients undergoing radical cystectomy for treatment of bladder cancer clinically staged as no greater than T2, N0
Indicated and agreed between physician investigator and patient to have an incontinent conduit as the diversion mechanism of choice post cystectomy
You may not be if
History of other cancer within the past 5 years (except non metastatic prostate or non melanoma skin cancer)
Evidence of cancer metastasis
History of any pelvic radiation or non-pelvic radiation within past 5 years
Debilitating cardiac or pulmonary disease
Expected need for chemotherapy within 3 months post cystectomy